GREENWICH LIFESCIENCES INC (GLSI) Stock Price, Quote, News and Overview
NASDAQ:GLSI - Nasdaq - US3968791083 - Common Stock - Currency: USD
GLSI Quote, Performance and Key Statistics
11.95
-0.09 (-0.75%)
The current stock price of GLSI is 11.95 USD. In the past month the price decreased by -8.08%. In the past year, price decreased by -7.58%.
GLSI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About GLSI
Company Profile
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 3 full-time employees. The company went IPO on 2020-09-25. The firm is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. The company has commenced a Phase III clinical trial, Flamingo-01 an immunotherapy to prevent breast cancer recurrences.
Company Info
GREENWICH LIFESCIENCES INC
3992 Bluebonnet Dr, Building 14
Stafford Texas TEXAS 33954 US
CEO: Snehal Patel
Employees: 5
Company Website: https://greenwichlifesciences.com
Investor Relations: https://investor.greenwichlifesciences.com/sec-filings/all-sec-filings
Phone: 12034343290
GREENWICH LIFESCIENCES INC / GLSI FAQ
What is the stock price of GREENWICH LIFESCIENCES INC today?
The current stock price of GLSI is 11.95 USD. The price decreased by -0.75% in the last trading session.
What is the ticker symbol for GREENWICH LIFESCIENCES INC stock?
The exchange symbol of GREENWICH LIFESCIENCES INC is GLSI and it is listed on the Nasdaq exchange.
On which exchange is GLSI stock listed?
GLSI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GREENWICH LIFESCIENCES INC stock?
7 analysts have analysed GLSI and the average price target is 38.76 USD. This implies a price increase of 224.35% is expected in the next year compared to the current price of 11.95. Check the GREENWICH LIFESCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GREENWICH LIFESCIENCES INC worth?
GREENWICH LIFESCIENCES INC (GLSI) has a market capitalization of 157.02M USD. This makes GLSI a Micro Cap stock.
How many employees does GREENWICH LIFESCIENCES INC have?
GREENWICH LIFESCIENCES INC (GLSI) currently has 5 employees.
What are the support and resistance levels for GREENWICH LIFESCIENCES INC (GLSI) stock?
GREENWICH LIFESCIENCES INC (GLSI) has a support level at 11.49 and a resistance level at 12.03. Check the full technical report for a detailed analysis of GLSI support and resistance levels.
Should I buy GREENWICH LIFESCIENCES INC (GLSI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GLSI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GLSI, evaluating the profitability, health, valuation and growth aspects
- GREENWICH LIFESCIENCES INC (GLSI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GREENWICH LIFESCIENCES INC (GLSI) Sales and EPS estimates to see what analysts future expectations are.
- GREENWICH LIFESCIENCES INC (GLSI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GREENWICH LIFESCIENCES INC (GLSI) Insider and Institutional Ownership to learn about the owners and their transactions.
- GREENWICH LIFESCIENCES INC (GLSI) Stock Chart to make your own analysis
- GREENWICH LIFESCIENCES INC (GLSI) Latest news and press-releases to stay up to date.
Does GREENWICH LIFESCIENCES INC (GLSI) stock pay dividends?
GLSI does not pay a dividend.
When does GREENWICH LIFESCIENCES INC (GLSI) report earnings?
GREENWICH LIFESCIENCES INC (GLSI) will report earnings on 2025-04-14, after the market close.
What is the Price/Earnings (PE) ratio of GREENWICH LIFESCIENCES INC (GLSI)?
GREENWICH LIFESCIENCES INC (GLSI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.8).
What is the Short Interest ratio of GREENWICH LIFESCIENCES INC (GLSI) stock?
The outstanding short interest for GREENWICH LIFESCIENCES INC (GLSI) is 10.9% of its float. Check the ownership tab for more information on the GLSI short interest.
GLSI Technical Analysis
GLSI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLSI. While GLSI has a great health rating, there are worries on its profitability.
GLSI Financial Highlights
Over the last trailing twelve months GLSI reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS decreased by -14.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -180.18% | ||
| ROE | -210.64% | ||
| Debt/Equity | 0 |
GLSI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to GLSI. The Buy consensus is the average rating of analysts ratings from 7 analysts.